Double-blind RCTs on Magnesium Bisglycinate NMDA/GABA receptor modulation and nocturnal cortisol reduction, antidepressant remission meta-analyses, SAMe augmentation trials, and optical smartwatch HRV validation studies. Explore 674 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Cognitive impairment and cognitive frailty are associated with multiple demographic, clinical, and dialysis-related factors but represent distinct outcomes that should be interpreted separately. Further high-quality prospective studies are warranted.
J Orthop Sports Phys Ther 2026;56(11):710-723. doi:10.2519/jospt.2026.14210 .
Youth with obesity performed significantly worse than normal-weight peers on inhibition (g + = -0.193), cognitive flexibility (g + = -0.499), working memory (g + = -0.652), verbal fluency (g + = -0.420), attention (g + = -0.526), and IQ (g + = -0.288); planning could not be estimated.
Vitiligo is significantly associated with elevated risks of depression and suicidality. These findings highlight the need for heightened clinical awareness and integrated psychological care to improve patients' overall well-being and quality of life.
No serious side effects were reported.
Hippocampal gray matter volume remained stable across all three groups, whereas hippocampal functional connectivity declined in healthy controls but remained stable in both intervention groups, consistent with possible functional neural maintenance.
In individuals with remitted psychotic depression, continuation treatment with sertraline plus olanzapine was associated with better outcomes in HRQOL domains directly relevant to mental health than treatment with sertraline...
Based on modeling data, inebilizumab had greater long-term efficacy than historical immunosuppressants.
Patients with poorer disease-specific QoL, but not necessarily those with more severe symptoms or higher scores for anxiety and depression, are particularly likely to incur higher annual costs.
Short-term treatment with daridorexant does not impair sleep-disordered breathing and may improve sleep in patients with severe OSA.
Conclusions: Adjunctive lumateperone 42 mg did not worsen sexual functioning and was not associated with treatment-related sexual dysfunction in patients with MDD with inadequate response to ADT.
Exploratory outcomes include the incidence of depressive and anxiety symptoms at 90 days.
Joint profiles were differentially associated with NfL (P = 0.0427) and brain-PAD (P = 0.0296).
Three external reference anchors were used to assess known-groups validity, based on clinician and study partner ratings of disease severity over time.
Mediation analysis supports a bile-acid-mediated suppression of inflammatory pathways linking microbial changes to antidepressant effects.
In this study, fluoxetine combined with CBT showed no significant advantage over fluoxetine single-drug treatment.
The mean CFB in MADRS demonstrated separation between esmethadone and placebo arms for patients with a baseline score of 35 or higher.
Safety outcomes are symptomatic intracranial haemorrhage within 36 hours, death within 90 days and mRS 5-6 at 90 days.
Nipocalimab + SOC demonstrated early and sustained fatigue and HRQoL improvements over 24 weeks.
We found that pre-treatment frontopolar beta duration was significantly correlated with depression score change, with greater degree of symptom response linked to shorter beta events at baseline.
Of 31 participants screened, 22 were randomized; 1 placebo-assigned participant did not meet the NRS ≥5 criterion and was excluded, leaving 21 for analysis (IFT: 11; placebo: 10).
Findings suggest that PATH significantly reduces anxiety and depressive symptoms, particularly with continued use.
Nipocalimab treatment improves gMG symptoms earlier than placebo and provides meaningful and long-term sustained disease control over 24 weeks among participants with gMG.
In addition to significant improvement on five out of eight Marder Positive Symptom items, the following non-Positive PANSS items were notable for being especially responsive to lurasidone treatment in terms of significant...
Daridorexant warrants further investigation in COMISA.
EXCAP may reduce CRCI and mental fatigue, particularly in patients receiving 2-week cycles of chemotherapy.
Notably, the incidence of adverse effects did not differ significantly among the three groups.
MADRS total score (mean change, -8.9, nominal P < 0.0001), CGI-BP-S total score (-2.3, nominal P < 0.0001), and CGI-BP-S depression subscore (-1.3, nominal P < 0.0001) improved over time, from baseline to Day 175.
CONCLUSION: Prophylactic administration of 0.5 µg/kg dexmedetomidine reduced early postoperative sleep disturbances associated with propofol, primarily by preserving REM sleep and mitigating TST and WASO fluctuations.
Epilepsy-DOOR showed similar effect sizes but slightly reduced power when compared with responder rate.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
